Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CMND

Clearmind Medicine Inc

Apr 19 • 04:00PM ET

1.18

Dollar change +0.01
Percentage change 0.59	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-31.40	Insider Own	7.75%	Shs Outstand	3.17M	Perf Week	-4.44%
Market Cap	3.76M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.92M	Perf Month	-2.87%
Income	-8.09M	PEG	-	EPS next Q	-	Inst Own	7.38%	Short Float	6.12%	Perf Quarter	14.60%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.23	Perf Half Y	-75.77%
Book/sh	1.59	P/B	0.75	EPS next Y	-	ROA	-109.65%	Short Interest	0.18M	Perf Year	-92.96%
Cash/sh	2.96	P/C	0.40	EPS next 5Y	-	ROE	-181.87%	52W Range	0.92 - 24.67	Perf YTD	-57.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-24.88%	ROI	-159.49%	52W High	-95.20%	Beta	-1.71
Dividend TTM	-	Quick Ratio	1.96	Sales past 5Y	0.00%	Gross Margin	-	52W Low	28.73%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	1.96	EPS Y/Y TTM	79.51%	Oper. Margin	0.00%	RSI (14)	44.08	Volatility	7.62% 8.32%
Employees	-	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	96.22%	Payout	-	Rel Volume	0.15	Prev Close	1.18
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	769.60K	Price	1.18
SMA20	-0.24%	SMA50	-12.85%	SMA200	-77.73%	Trades		Volume	112,724	Change	0.59%

Apr-17-24 07:49AM	Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders (GlobeNewswire)
Apr-10-24 07:17AM	Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders (GlobeNewswire)
Apr-09-24 08:07AM	Clearmind Medicine CEO Issues Letter to Shareholders (GlobeNewswire) +17.86%
Mar-27-24 09:12AM	Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression (GlobeNewswire)
08:55AM	SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression (GlobeNewswire)
07:55AM	Loading…
Mar-19-24 07:55AM	Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China (GlobeNewswire)
Mar-13-24 08:14AM	Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial (GlobeNewswire) -7.48%
07:30AM	Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange (GlobeNewswire)
Feb-27-24 07:58AM	SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds (GlobeNewswire)
07:58AM	Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds (GlobeNewswire)
Feb-26-24 10:37AM	Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours (News Direct) -7.98%
Feb-23-24 07:06AM	Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder (GlobeNewswire)
Feb-20-24 07:14AM	SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds (GlobeNewswire) +14.07%
07:14AM	Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds (GlobeNewswire)
Feb-11-24 01:59PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
07:51AM	Loading…
Feb-05-24 07:51AM	Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China (GlobeNewswire)
Feb-01-24 08:15AM	Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center (GlobeNewswire) +20.28%
Jan-16-24 12:20PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND) (ACCESSWIRE) -5.88%
11:19AM	Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement (GlobeNewswire)
Jan-11-24 09:28AM	Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement (GlobeNewswire) -43.00%
08:53AM	Why Is Clearmind Medicine (CMND) Stock Down 24% Today? (InvestorPlace)
Jan-10-24 07:18AM	Clearmind Medicine Completed Type A Meeting with the FDA (GlobeNewswire) +41.55%
Jan-04-24 07:18AM	SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments (GlobeNewswire) -6.51%
07:18AM	Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments (GlobeNewswire)
Dec-14-23 08:26AM	Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards (GlobeNewswire)
Dec-05-23 01:09PM	Why Is Clearmind Medicine (CMND) Stock Up 50% Today? (InvestorPlace) +14.10%
08:47AM	Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment (GlobeNewswire)
Dec-01-23 08:14AM	Weight loss MEAI: Clearmind Medicines Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial (GlobeNewswire) +18.29%
Nov-28-23 08:25AM	Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment (GlobeNewswire) +10.34%
Nov-27-23 08:55AM	Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures (GlobeNewswire) -16.21%
08:15AM	Loading…
Nov-21-23 08:15AM	Clearmind Medicine Announces 1-for-30 Reverse Share Split (GlobeNewswire)
Nov-17-23 04:15PM	Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance (GlobeNewswire) +7.36%
Nov-15-23 07:37AM	Clearmind Medicine Announces Shareholders Meeting Results (GlobeNewswire)
Nov-09-23 09:20AM	Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities (GlobeNewswire) -6.23%
Oct-05-23 09:00AM	Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th (GlobeNewswire) -5.70%
Sep-28-23 09:00AM	Clearmind Medicine to Present at the LD Micro Main Event XVI Investor Conference on October 4th (Newsfile)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-19-23 10:30AM	Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND) (ACCESSWIRE)
Sep-18-23 12:16PM	Clearmind Medicine Closes US$2.25 Million Public Offering (GlobeNewswire)
Sep-14-23 09:23AM	Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering (GlobeNewswire) -54.14%
Sep-06-23 09:20AM	Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder (GlobeNewswire) +11.14%
Aug-14-23 08:25AM	Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company (GlobeNewswire) -8.49%
Aug-01-23 09:00AM	SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S. (GlobeNewswire)
09:00AM	Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio (GlobeNewswire)
Jul-17-23 04:15PM	Clearmind Medicine Announces Share-Based Payment for the Company's Consultants (GlobeNewswire)
Jul-11-23 08:30AM	Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board (GlobeNewswire)
Jun-16-23 09:05AM	SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome (GlobeNewswire)
09:05AM	Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome (GlobeNewswire)
Jun-09-23 09:30AM	Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity (GlobeNewswire)
May-22-23 08:30AM	Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder (GlobeNewswire)
May-19-23 04:15PM	Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-17-23 09:00AM	Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity (GlobeNewswire)
May-12-23 09:00AM	Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder (GlobeNewswire) +9.51%
May-09-23 04:15PM	Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants (GlobeNewswire)
May-08-23 08:30AM	Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam (GlobeNewswire)
May-02-23 08:30AM	Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial (GlobeNewswire)
Apr-27-23 08:30AM	Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial (GlobeNewswire) -15.03%
Apr-21-23 08:30AM	SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression (GlobeNewswire)
08:30AM	Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression (GlobeNewswire)
Apr-20-23 05:37AM	Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial (GlobeNewswire) +13.13%
Apr-10-23 11:00AM	Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Public Offering for Clearmind Medicine Inc. (NASDAQ: CMND) (ACCESSWIRE) +11.81%
Apr-06-23 04:15PM	Clearmind Medicine Closes US$3.5 Million Public Offering (GlobeNewswire)
Apr-04-23 09:00AM	Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering (GlobeNewswire) -62.21%
Mar-16-23 08:30AM	Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder (GlobeNewswire) -5.88%
Mar-14-23 08:55AM	Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board (GlobeNewswire) -10.12%
Feb-22-23 08:00AM	SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds (GlobeNewswire)
08:00AM	Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds (GlobeNewswire)
Feb-15-23 08:30AM	SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US (GlobeNewswire)
08:30AM	Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US (GlobeNewswire)
Feb-14-23 08:30AM	Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv (GlobeNewswire) -6.46%
Feb-08-23 08:30AM	Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity (GlobeNewswire)
Jan-31-23 09:00AM	Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound (GlobeNewswire)
Jan-25-23 08:30AM	Hebrew University' Yissum and Israeli Biotech Clearmind Medicines Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023 (GlobeNewswire)
Jan-19-23 09:00AM	Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalems Tech Transfer Company, Yissum (GlobeNewswire)
Jan-17-23 09:00AM	Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment (GlobeNewswire) -11.13%
Jan-10-23 08:30AM	Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial (GlobeNewswire) +21.23%
Jan-05-23 09:00AM	Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial (GlobeNewswire) +7.36%
Jan-04-23 08:40AM	Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com (ACCESSWIRE)
Dec-29-22 06:00AM	Clearmind Medicine Announces Shareholders Meeting Results (GlobeNewswire)
Dec-28-22 09:00AM	Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder (GlobeNewswire) -11.38%
Dec-22-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani (ACCESSWIRE)
Dec-21-22 09:00AM	Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute (GlobeNewswire)
Dec-15-22 09:00AM	Israeli Based Biotech Company Clearmind Medicine Incs CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders (GlobeNewswire) +26.77%
Dec-13-22 09:00AM	Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100 (GlobeNewswire) +11.88%
Dec-09-22 09:02AM	Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute (GlobeNewswire)
Dec-01-22 07:39PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -6.97%
Nov-23-22 08:45AM	Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial (GlobeNewswire)
Nov-17-22 12:15PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $7.5 Million Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ: CMND) (ACCESSWIRE)
11:43AM	Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market (GlobeNewswire)
Mar-23-22 11:58AM	Clearmind Medicine to Partner with Microdose for Psychedelic Capital: Mar 2022 on Thursday, March 24th (Newsfile) -5.43%
Mar-17-22 08:00AM	SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial (PR Newswire) +12.33%

Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMND

Clearmind Medicine Inc

Upgrade your FINVIZ experience